ASCO 2015 Highlights

Sunitinib (Sutent; Pfizer) is the second new option for the treatment of metastasized or unresectable locally advanced progressive pancreatic neuroendocrine cancerous tumors.

Read Article

New Indication for Everolimus for Neuroendocrine Pancreatic Cancer

FDA Approvals, News & Updates

June 2011, Vol 2, No 3

Read Article

FDA Accelerates Abiraterone Approval for Advanced Prostate Cancer

FDA Approvals, News & Updates

June 2011, Vol 2, No 3

Read Article

Vandetanib First Drug Indicated for Medullary Thyroid Cancer

FDA Approvals, News & Updates

June 2011, Vol 2, No 3

The US Food and Drug Administration (FDA) approved the orphan drug vandetanib (trade name pending; AstraZeneca), a tyrosine kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease.

Read Article

Peginterferon Alfa-2b for Metastatic Melanoma after Definitive Surgical Resection

FDA Approvals, News & Updates

April 2011, Vol 2, No 2

Read Article

Sorafenib Active Third-Line in Refractory GIST

By Caroline Helwick

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Read Article

Hypertension a Good Sign in Patients Receiving Sunitinib

Genitourinary Cancers Symposium